AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Epimmune provides update on cancer and HIV clinical development programmes.
(From Chemical Business NewsBase - Press Release)
Epimmune Inc provided an update of ongoing clinical development programmes with its EP-2101 therapeutic cancer and EP-1090 therapeutic HIV vaccines Epimmune conducted two Phase I clinical trials of EP-2101 in the US, with stage IIB/IIIA non-small cell lung (NSCL) cancer and stage III colorectal cancer patients. Patients enrolled in the trials previously had surgery to remove all detectable cancer cells and were expected to have normal immune system function. Each patient who completed the trial received six injections of the vaccine at three-week intervals. Data from 16 patients with either stage IIB/IIIA NSCL or stage …
